Skip to main content

Table 1 Baseline characteristics of the study population (n = 58)

From: Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients

Patient characteristics Resection (n = 15) Non-resection (n = 43) Total (n = 58) p-value
Age (years) 60.0 ± 10.5 62.8 ± 8.4 62.1 ± 9.0 0.292
Male, n (%) 6 (40.0%) 28 (65.1%) 34 (58.6%) 0.163
ECOG score, n (%)     0.531
 0 8 (53.3%) 17 (39.5%) 25 (43.1%)  
 1 7 (46.7%) 26 (60.5%) 33 (56.9%)  
DM, n (%) 6 (40.0%) 20 (46.5%) 26 (44.8%) 0.892
Tumor size (cm) 3.7 ± 0.7 3.9 ± 1.5 3.8 ± 1.3 0.434
Tumor location, n (%)     0.542
 Head/neck 8 (53.3%) 31 (72.1%) 39 (67.2%)  
 Body/tail 7(46.7%) 12 (27.9%) 19 (32.8%)  
Vessel invasion, n (%)     0.266
 Artery 2 (13.3%) 9 (20.9%) 11 (19.0%)  
 Vein 0 (0.0%) 5 (11.6%) 5 (8.6%)  
 Both 13 (86.7%) 29 (67.4%) 42 (72.4%)  
CA 19–9 (U/mL) 576 ± 1,220 963 ± 1,833 863 ± 1,695 0.452
CEA (ng/mL) 9.2 ± 19.3 5.4 ± 10.1 6.4 ± 13.0 0.469
FOLFIRINOX cycles [median (range)] 11 (2–16) 8 (1–20) 9 (1–20) 0.193
 ≥ 6 cycles 14 (93.3%) 33 (76.7%) 47 (81.0%) 0.304
cRDI (%) 72.6 ± 12.4 66.4 ± 15.2 68.0 ± 14.7 0.164
 ≥ 70% 8 (53.3%) 21 (48.8%) 29 (50.0%) 1.000
BMI (kg/m2) 22.7 ± 2.6 21.3 ± 3.0 21.7 ± 2.9 0.110
SM area (cm2) 107.4 ± 26.6 113.3 ± 24.4 111.8 ± 24.9 0.435
AT area (cm2) 211.4 ± 66.3 198.8 ± 91.9 202.1 ± 85.6 0.627
  1. The data are presented as mean ± standard deviation or n (%)
  2. ECOG Eastern Cooperative Oncology Group, DM diabetes mellitus, CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, cRDI corrected relative dose intensity, BMI body mass index, SM skeletal muscle, AT adipose tissue